The FDA Lifted the Clinical Hold on Solid Biosciences’ IGNITE DMD Phase 1/2 Trial Sending the Stock Price Over 131%

Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA
Solid Biosciences (SLDB) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical hold placed on the Company’s IGNITE DMD Phase 1/2 clinical trial.

The FDA had requested further manufacturing information, updated safety and efficacy . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.